Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [5284]

larotrectinib receives first tumour-agnostic licence in EU

larotrectinib receives first tumour-agnostic licence in EU

Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer

Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated...

FDA approves daratumumab for transplant-eligible multiple myeloma

FDA approves daratumumab for transplant-eligible multiple myeloma

ESMO 2019: Targeted therapy slows progression of advanced prostate cancer

ESMO 2019: Targeted therapy slows progression of advanced prostate cancer

ESMO 2019: New combination therapy offers bowel cancer patients extra treatment option

ESMO 2019: New combination therapy offers bowel cancer patients extra treatment option

ESMO 2019: PARP inhibitor plus chemotherapy improves progression-free survival for advanced ovarian cancer patients

ESMO 2019: PARP inhibitor plus chemotherapy improves progression-free survival for advanced ovarian cancer patients

ESMO 2019: Front-line osimertinib improves overall survival in EGFR-mutation positive NSCLC

ESMO 2019: Front-line osimertinib improves overall survival in EGFR-mutation positive NSCLC

Scientists tackle potential drug resistance by using new single-cell genetic method

Scientists tackle potential drug resistance by using new single-cell genetic method

Oncologists respond swiftly to FDA safety alerts

Oncologists respond swiftly to FDA safety alerts

Discovery could improve MDS cancer treatment

Discovery could improve MDS cancer treatment

More from ecancer